Nguyen, Ai-LanHavrdova, Eva KubalaHorakova, DanaIzquierdo, GuillermoKalincik, Tomasvan der Walt, AnnekeTerzi, MuratAlroughani, RaedDuquette, PierreGirard, MarcPrat, AlexandreBoz, CavitSola, PatriziaFerraro, DianaLugaresi, AlessandraLechner-Scott, JeannetteBarnett, MichaelGrand'Maison, FrancoisGrammond, PierreRamo-Tello, CristinaTurkoglu, RecaiMcCombe, PamelaPucci, EugenioTrojano, MariaGranella, FrancoSpitaleri, DanieleVan Pesch, VincentSoysal, AysunOreja-Guevara, CeliaVerheul, FreekVucic, SteveHodgkinson, SuzanneSlee, MarkAmpapa, RadekPrevost, JulieMenoyo, Jose Luis SanchezSkibina, OlgaSolaro, ClaudioOlascoaga, JavierShaw, CameronMadsen, Klaus GregaardNaidoo, KerishaHyde, RobertButzkueven, HelmutJokubaitis, VilijaMSBase Study Group2023-01-252023-01-252019-01-03http://hdl.handle.net/10668/13395Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RRMS) may be increasing. To retrospectively determine incidence of pregnancy, DMT exposure and pregnancy outcomes in women with RRMS. We identified all women with RRMS aged 15-45 years in the MSBase Registry between 2005-2016. Annualised pregnancy incidence rates were calculated using Poisson regression models. DMT exposures and pregnancy outcomes were assessed. Of 9,098 women meeting inclusion criteria, 1,178 (13%) women recorded 1,521 pregnancies. The annualised incidence rate of pregnancy was 0.042 (95% CI 0.040, 0.045). A total of 635 (42%) reported pregnancies were conceived on DMT, increasing from 27% in 2006 to 62% in 2016. The median duration of DMT exposure during pregnancy was 30 days (IQR: 9, 50). There were a higher number of induced abortions on FDA pregnancy class C/D drugs compared with pregnancy class B and no DMT (p = 0.010); but no differences in spontaneous abortions, term or preterm births. We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.enIncidenceMultiple sclerosisOutcomesPregnancyTherapyAdolescentAdultCohort StudiesFemaleFollow-Up StudiesHumansImmunologic FactorsIncidenceMultiple Sclerosis, Relapsing-RemittingPregnancyPregnancy ComplicationsPregnancy OutcomeRegistriesRetrospective StudiesYoung Adultresearch article3062386410.1016/j.msard.2019.01.0032211-0356